Introduction
Cellular response to DNA damage (genotoxic stress) is complex and involves a variety of molecules. Ultraviolet radiation (UV) is a potent genotoxic stress-inducing agent. In general, it induces the formation of pyrimidine dimmers and other photoproducts that appear to block transcription and DNA replication (de Laat et al., 1999; Hoeijmakers, 2001) . The UV-induced DNA damage is generally repaired by nucleotide excision repair (NER) pathway (de Laat et al., 1999 , Friedberg, 2003 , and defects in the NER pathway are believed to be responsible for UV-induced mutagenesis and carcinogenesis. Cellular response to UV not only activates DNA damage repair pathway but also cell cycle checkpoints that allow time for DNA repair or apoptosis, if the damage is excessive, to eliminate the damaged cells. ATR kinase and its downstream kinase Chk1 are believed to transduce some of these signals (Guo et al., 2000; Walworth, 2000; Bao et al., 2001; Heffernan et al., 2002; Unsal-Kacmaz et al., 2002) . Several lines of evidence also implicate other kinases such as JNK and p38 as well as activation of transcription factors in cellular response to genotoxic stress (Bulavin et al., 1999; Buschmann et al., 2001) .
Tumor suppressor p53 is a major player in cellular response to genotoxic stress. p53 gene is one of the most frequently mutated genes in human cancers. A large body of evidence suggests that p53 protein is a central connection point for a variety of signal transduction pathways, especially those linked to cellular stress response (reviewed in Vogelstein, 2000) . p53 functions as a transcription factor and mediates its effect by modulating the expression of its downstream target genes. The p53 protein contains an amino (N)-terminal transactivation domain, a central DNA-binding domain and a carboxyl (C)-terminal oligomerization domain (reviewed in el-Deiry, 1998; Giaccia and Kastan, 1998; Ryan et al., 2001) . The central domain facilitates sequence-specific DNA binding to p53 response elements present within the regulatory regions of a number of p53-regulated genes (reviewed in el-Deiry, 1998; Giaccia and Kastan, 1998; Ryan et al., 2001) . p53 binds to its response element as a homotetramer and its activity is also affected via post-translational modifications including phosphorylation and acetylation (reviewed in el-Deiry, 1998; Giaccia and Kastan, 1998; Ryan et al., 2001) . The p53 protein has been implicated in a variety of cellular processes but its role in cell cycle arrest and apoptosis remains undisputed. It is known to activate the expression of several genes whose products are implicated in inducing cell cycle arrest or apoptosis (reviewed in el-Deiry, 1998; Giaccia and Kastan, 1998; Sheikh and Fornace, 2000; Vogelstein, 2000; Ryan et al., 2001; Alarcon-Vargas and Ronai, 2002; Bargonetti and Manfredi 2002) . Some of these genes are transcriptionally upregulated by p53 via direct sequencespecific binding to p53 response elements, while for others the mechanisms of p53-dependent regulation remain to be elucidated. p21 and 14-3-3s are the major downstream targets of p53 that are implicated in inducing cell cycle arrest, whereas Bax, Fas, death receptor 5 (DR5), NoxA, p53AIP1 and similar other molecules are among the downstream targets that are implicated in mediating the p53-induced apoptosis (reviewed in el-Deiry, 1998; Giaccia and Kastan, 1998; Sheikh and Fornace, 2000; Vogelstein, 2000; Ryan et al., 2001; Alarcon-Vargas and Ronai, 2002; Bargonetti and Manfredi 2002) . p53 also upregulates the expression of genes whose products are involved in controlling processes such as DNA damage repair, angiogenesis and RNA metabolism (Fontanini et al., 1999; Hwang et al., 1999; Tanaka et al., 2000; Adimoolam and Ford, 2002) .
p53 has also been found to mediate its effect by downregulating the expression of several genes that encode important cell cycle regulatory and antiapoptosis proteins including Cdc2, cyclin A, cyclin B1, cyclin E, Bcl2, Survivin, IAP1 and IAP2 (Desdouets et al., 1996; Innocente et al., 1999; Gottifredi et al., 2001; Kannan et al., 2001; Taylor et al., 2001; Hoffman et al., 2002) . The mechanisms by which p53 transcriptionally upregulates the expression of its downstream target genes have been extensively investigated. A large body of evidence has now established that p53, as a homotetramer, activates the expression of its target genes by directly binding to a response element that is composed of two copies of the consensus motif 'RRRCWWGYYY' (where R ¼ purine; Y ¼ pyrimidine; W ¼ adenine or thymine), separated by 0-13 bases (el-Deiry et al., 1992; Resnick-Silverman et al., 1998) . However, the molecular mechanisms by which p53 downregulates the expression of target genes are poorly understood.
Here we report the cloning and characterization of a novel gene, which we have named PDRG (p53 and DNA damage-regulated gene), which is upregulated by UV but downregulated by p53. MDR1 and 53BP2 are two other genes that have been reported to be regulated in a similar manner. MDR1 codes for a protein that confers multidrug resistance in a variety of tumor cells, while 53BP2 encodes a protein of unknown function but is believed to play a role in UVinduced apoptosis (Lopez et al., 2000; Johnson et al., 2001) . PDRG does not exhibit sequence homology to MDR1 or 53BP2; it displays a distinct expression pattern in the cytoplasm, suggesting that it appears to reside in a subcellular compartment. As is the case for 53BP2, expression of exogenous PDRG promotes decreased clonogenic survival after UV irradiation, which suggests a functional similarity between PDRG and 53BP2.
Results

Molecular cloning of the human PDRG gene
Using a UV-treated low-ratio hybridization subtractionenriched cDNA library, we have previously reported the cloning and characterization of two novel UV-inducible genes that code for an RNA-binding protein and translation initiation factor 1 (Sheikh et al., 1997b (Sheikh et al., , 1999 . In our continued efforts to identify novel molecular markers that affect cellular response to genotoxic stress, we screened several partial-length EST (expressed sequence tag) clones to identify those regulated by genotoxic stress-inducing agents. One partial-length EST hybridized to a transcript of approximately 1.4 kb that was upregulated by UV and was subsequently named PDRG. Further searches in the GenBank database revealed several human and mouse ESTs that were identical to PDRG. We analysed 153 human EST clones that were similar to each other as well as to PDRG. Two human EST clones (Accession #s BG037043, BF797584) and two mouse EST clones (Accession #s BF180486, AW988681) representing PDRG from different tissues (human: testis and lymphoma; mouse: mammary gland and mammary tumor) were obtained and sequenced in their entirety. All these clones contained a 133 amino acid-long open reading frame (ORF) corresponding to PDRG proteins with predicted molecular mass of 15.5 and 15.3 kDa for human and mouse, respectively. The longest cDNA clone of 1365 bp in size is in close agreement with the PDRG mRNA of approximately 1.4 kb indicating it to be near full-length cDNA of PDRG. The cDNA and predicted amino-acid sequences of human PDRG are shown in Figure 1 . The deduced amino-acid sequences of human and mouse PDRG proteins are aligned in Figure 2 and as is shown, the human PDRG protein displays about 92% identity to murine PDRG. Database searches did not identify any known genes/proteins that were identical to human or mouse PDRG indicating that PDRG is a novel gene. Motif searches suggest that a helix-turn-helix motif may exist at the C-terminal end of both human and mouse PDRG proteins (Figures 1 and 2 ).
Genomic organization, chromosomal localization and tissue distribution of PDRG
A blast analysis of the genomic sequences in the GenBank database enabled us to ascertain the chromosomal localization and the genomic organization of the human and mouse PDRG genes. The human PDRG is located on chromosome 20q11 and the complete gene contains five exons that are separated by four introns. Each intron has the perfect intron splicing motif
The genomic organization of mouse PDRG is similar to that of human and it resides on chromosome 2. Table 1 shows the intron/ exon and splice site sequences of human and murine PDRG. To determine the tissue distribution of human PDRG, we utilized a commercially available Northern blot carrying poly(A) þ RNA from various human tissues. The blot was probed with a radiolabeled probe corresponding to human PDRG cDNA, and Figure 3 shows the relative abundance of human PDRG in various tissues. As is shown (Figure 3 ), the human PDRG is expressed as a transcript of approximately 1.4 kb in various tissues but its expression is specifically high in testis.
PDRG is upregulated by UV but downregulated by p53 Figure 4 shows that UV upregulates the expression of PDRG in various human cell lines including MCF-7, TSUPr1 and H1299 cells corresponding to cancers of the breast, bladder/prostate and lung, respectively. As is shown, PDRG mRNA levels increase within 6 h of UV irradiation, peak at 12 h ( Figure 4 ) and decline by 24 h (data not shown). p21 WAF1 (hereafter refer to as p21) is a known UV upregulated gene; UV-mediated upregulation of p21 predominantly occurs in a p53-dependent manner. Therefore, we probed the same blots with p21 cDNA to ascertain the effect of UV on p21 expression, and as expected, p21 mRNA levels are also upregulated following UV exposure in MCF-7 cells harboring wildtype p53 (Figure 4) . The p53-negative TSUPr1 and H1299 cells exhibited very low constitutive levels of p21 and UV did not appreciably induce the expression of p21 in these cells (data not shown).
p53 is activated following UV exposure and is a major mediator of UV-induced stress response (Bulavin et al., 1999; Buschmann et al., 2001; Seker et al., 2003) . Figure 2 Amino-acid sequence alignment of human and mouse PDRG proteins. Sequences were aligned using MacVector (Genetics Computer Groups, Madison, WI, USA); identities and conserved changes between human and mouse proteins are boxed Figure 3 Tissue distribution of human PDRG. A Northern blot containing poly(A) þ RNA from human brain, heart, liver, lung, spleen, stomach, testis and skeletal muscle was purchased from Panomics (Redwood City, CA, USA) and probed with a 32 Plabeled human PDRG cDNA probe. The same blot was subsequently probed with a human b-actin cDNA probe p53 and DNA damage-regulated gene X Luo et al Following UV-induced activation, p53 has been shown to transcriptionally upregulate the expression of several of its downstream target genes. UV can also up or downregulate the expression of certain genes in a p53-independent manner (Fornace, 1992) . Results presented in Figure 4 indicate that UV upregulates PDRG expression in p53-null cells (H1299) or those that harbor mutant p53 (TSUPr1). However, the contribution of p53 in UV-mediated upregulation of PDRG in MCF-7 cells that contain wild-type p53 cannot be excluded. Next, we undertook two approaches to more directly explore the contribution of p53 in UV-induced upregulation of PDRG. In the first approach, we utilized DLD1 human colon cancer cells that harbor 'Bidirectional Tet Expression Vector' system controlling the inducible expression of exogenous wild-type p53 . In these cells, the expression of p53 is repressed when the cells are grown in the presence of tetracycline or doxycycline, but induced when the antibiotic is removed from the growth medium . As shown in Figure 5a , cells grown in the presence of doxycycline (wild-type p53 is repressed) exhibit higher PDRG mRNA levels than those growing in the absence of this antibiotic (wild-type p53 is induced). These results indicate that p53 induction promotes PDRG downregulation. We also investigated the effect of p53 induction on p21, which is a known p53-inducible gene. Same blots were probed with a p21 cDNA probe and as is shown (Figure 5a ), p21 expression is upregulated following doxycycline removal when wild-type p53 is induced, a finding which confirms the functionality of wild-type p53 following doxycycline removal in these cells. The results that p53 promotes PDRG downregulation were surprising since, based on UV-induced upregulation of PDRG, we expected p53 to either not effect or upregulate the expression of PDRG.
For a second approach to further explore the role of p53 in UV regulation of PDRG, we used HCT116
and HCT116
(p53À/À) cells. HCT116 (p53 þ / þ ) cells harboring endogenous wild-type p53 and their isogenic counterparts HCT116
(p53À/À) lacking wild-type p53 were exposed to UV and Northern blot analyses were performed to ascertain the effect of UV on PDRG expression. As shown in Figure 5b , UV upregulates the expression of PDRG in both p53 wild-type and p53-null cells, indicating that UV upregulation of PDRG occurs in a p53-independent manner. UV regulation of p21, on the other hand, predominantly occurs in a p53-dependent manner since it is abrogated in p53-null cells (Figure 5b ). ) and harvested at the indicated postirradiation time points. Total RNA extraction and Northern blot analyses were performed as described in Materials and methods. The blots were probed with a 32 P-labeled human PDRG cDNA probe. The same blots were also probed with a 32 Plabeled human p21 cDNA probe. The p53-negative TSUPr1 and H1299 cells exhibited very low constitutive levels of p21, and UV irradiation did not appreciably alter its expression in these cells. Experiments were repeated and similar results were obtained p53 and DNA damage-regulated gene X Luo et al Interestingly, the p53-null HCT116 cells exhibit higher PDRG mRNA levels than their isogenic counterparts carrying wild-type p53 (Figure 5b ). These results indicate that while UV upregulates PDRG in a p53-independent manner, the deletion of p53 further enhances PDRG expression in these p53-null cells. The expression of p21 gene, on the other hand, shows an opposite pattern of regulation on the same blot ( Figure 5b ). These results further support the notion that PDRG is indeed negatively regulated by wild-type p53.
PDRG gene promoter regulation by p53, UV and Oct-1
The results so far indicate that UV upregulates PDRG expression in a p53-independent manner, and that p53 promotes downregulation of PDRG expression. To further investigate the molecular mechanisms of UVand p53-mediated regulation of PDRG, we cloned a 1.7-kb fragment carrying part of the noncoding region of the first exon and the 5 0 -flanking region of the human PDRG. Nucleotide sequence analysis (Figure 6a ) indicates that PDRG appears to lack a canonical TATA box but contains a TATA-like element 'TAATAA' at position -268 with respect to start codon. To confirm that this 1.7-kb 5 0 -flanking fragment of PDRG harbors promoter activity, we placed it upstream of a promoterless luciferase gene. In addition, we deleted a stretch of proximal sequence at position þ 1 to -138 from this construct. These reporter constructs were transiently transfected into MCF-7 cells and as is shown (Figure 6b ), the full-length fragment displays high levels of luciferase activity while deletion of the proximal sequence abolishes the PDRG promoter activity. These results confirm that the 1.7-kb fragment harbors the PDRG promoter activity, and that some key elements for activity of the basal promoter resides within the proximal 138 nucleotides.
p53 is known to upregulate the expression of genes by binding to its response element that is composed of two copies of the consensus motif 'RRRCWWGYYY' arranged in head-to-head and separated by 0-13 bases (el-Deiry et al., 1992; Resnick-Silverman et al., 1998; Johnson et al., 2001) . However, p53 is reported to also suppress gene expression by binding to the same consensus motifs but only if they are arranged in head-to-tail orientation (Johnson et al., 2001) . Analysis of the PDRG promoter sequence reveals that a putative p53-binding element is present at position -240/À214 that is arranged in head-to-tail with six nucleotides between the two repeats. Thus, PDRG promoter carries a p53 response element that is similar to those recently 0 -flanking 1.7-kb-fragment and the one lacking the proximal 138 nucleotides were placed upstream of promoterless luciferase cDNA into reporter vector pGL-basic. Each promoter reporter vector as well as parent vector without PDRG promoter sequence (pGL-basic) were independently transfected into MCF-7 human breast cancer cells plated in six-well plates, and luciferase activity was determined as described in Materials and methods. The relative luciferase activity of each construct is expressed as mean þ s.d. of three-independent wells; experiment was repeated and similar results were obtained p53 and DNA damage-regulated gene X Luo et al reported for genes that are downregulated by p53 (Johnson et al., 2001) . Recently, a novel cis-element has also been identified which is present in several p53 upregulated genes such as p21, PIG-3, PTGF-b1 and the likes (Wong et al., 2002) . This element, named p53TRE (p53 transcriptional repressor element) has a consensus sequence 'GYYDCCCAGGCTGGARTGSWR' (where R ¼ purine; Y ¼ pyrimidine; W ¼ adenine or thymine; S ¼ guanine or cytosine; D ¼ guanine or adenine or thymine), and is reported to suppress p53 transactivation in a position and promoter-independent manner (Wong et al., 2002) . PDRG promoter sequence analysis reveals the presence of a similar p53TRE at position -854/À834 (Figure 6a) .
Next, we investigated the effects of p53 on the promoter activity of PDRG. As shown in Figure 7a and b, p53 suppresses the PDRG promoter activity within 6 h and in a concentration-dependent manner. To rule out the possibility that p53-induced downregulation of PDRG promoter activity was not due to generalized toxicity from exogenous p53, we simultaneously also analysed the effect on reporter vectors PG13-luc and MG15-luc that harbor several copies of wild-type and mutated p53-binding elements, respectively (Majumder et al., 2001) . As shown in Figure 7c , p53 expectedly enhances the luciferase activity in PG13-luc transfected cells but not in cells transfected with MG15-luc carrying mutant p53-binding elements. Thus, these results confirm that p53-mediated downregulation of PDRG promoter activity is not due to generalized toxicity and is consistent with its downregulation of endogenous PDRG mRNA.
The sequence analysis of the PDRG promoter region indicates that there is one canonical Oct-1-binding element at position À689/À683. Recent evidence indicates that UV enhances the Oct-1 activity by posttranscriptionally increasing the levels of this transcription factor, which then transcriptionally increases the expression of UV-regulated genes (Zhao et al., 2000; Takahashi et al., 2001) . The presence of Oct-1-binding element in the promoter region of PDRG suggests that UV may upregulate this gene via Oct-1. Consistent with this notion, UV irradiation increases the PDRG promoter luciferase activity in MCF-7 cells (Figure 8a ) and constitutive expression of exogenous Oct-1 also strongly enhances PDRG promoter activity, suggesting that UV may indeed upregulate luciferase activity via Oct-1. The extent of PDRG promoter upregulation by Oct-1 is much more pronounced than that occurs with UV alone (Figure 8a and b) . It is possible that UV activation of wild-type p53 in these cells may exert a negative effect on PDRG expression and consequently blunts the overall upregulation of PDRG by UV.
Subcellular localization of PDRG
PDRG codes for a novel protein that does not show high degree of similarity to any known protein in the databases. As a first step to gain an insight into the function of PDRG, we undertook experiments to determine its subcellular localization. To that end, we generated two different PDRG-GFP fusion constructs carrying GFP either at the N-or C-terminal ends of PDRG. Western blot analyses performed on transiently transfected 293 cells validated the expression as well as the correct size of the GFP-PDRG fusion proteins (data Figure 7 Wild-type p53 inhibits PDRG promoter activity. p53-null H1299 cells growing in six-well plates were transiently cotransfected with PDRG promoter luciferase construct (pGLfull) and either p53 expression vector or the same vector without p53 insert as described in Materials and methods. Cells were harvested and luciferase activity was measured. Exogenous wildtype p53 inhibits PDRG promoter activity in a time (a)-and dose (b)-dependent manner; values are expressed as mean þ s.d. of threeindependent wells for each bar. These experiments were performed several times and similar results were obtained. (c) Wild-type p53 increases luciferase activity from PG13-luc, which carries several copies of the wild-type p53-binding element, but not from MG15-luc that carries mutant binding sites p53 and DNA damage-regulated gene X Luo et al not shown). NIH3T3 cells were transiently transfected with PDRG-GFP fusion constructs or GFP vector alone and analysed by fluorescent microscopy. As shown in Figure 9 , GFP alone is diffusely distributed throughout the cells whereas PDRG-GFP appears as aggregates concentrated in discrete areas within cytosol indicating that it could be present within a subcellular organelle(s). Similar subcellular distribution was noted in HCT116 cells regardless of whether GFP was present at the N-or C-terminal ends of the PDRG. To ascertain the identity of the subcellular compartment in which PDRG resides, we simultaneously stained the GFP-PDRG-expressing cells with mitochondrial-or endoplasmic reticulum (ER)-specific dyes but PDRG did not display clear colocalization with mitochondrial-or ER-specific staining pattern (data not shown). These results thus suggest that PDRG is not a nuclear protein but appears to be present within a distinct subcellular compartment in the cytoplasm.
Expression of exogenous PDRG decreases clonogenic survival following UV irradiation
The transient expression of PDRG-GFP fusion protein in NIH3T3 or HCT116 cells does not induce obvious morphologic features of apoptosis, suggesting that overexpression of exogenous PDRG is tolerated by these cells and is not toxic. Therefore, we decided to establish stable transfectants expressing exogenous PDRG. To achieve this, we generated expression vector in which PDRG cDNA was fused with an HA-tag. HCT116 cells were then transfected with the expression vector carrying HA-tagged PDRG cDNA and the same vector without PDRG insert. Stable clones expressing exogenous PDRG were identified by Western blot analyses using anti-HA antibody. As shown in Figure 10 , pooled clones as well as single clones 14 and 16 exhibit exogenous PDRG expression. We selected clones 14 and 16 for subsequent studies to explore the effect of exogenous PDRG on their clonogenic survival after UV irradiation. As shown in Figure 11 , expression of exogenous PDRG clearly decreases the clonogenic survival following UV treatment indicating that the expression of exogenous PDRG sensitizes these cells to UV.
Discussion
We have reported the cloning and characterization of PDRG, a novel gene, which is upregulated by UV but downregulated by p53. PDRG from both human and mouse is predicted to encode a protein of 133 amino acids. The human and murine PDRG proteins are highly homologous but do not show significant similar- ity to any known genes in the databases. Although the function of PDRG is not known at the present time, it appears to harbor a helix-turn-helix-like motif at the Cterminal end. Such motifs are involved in proteinprotein and protein-DNA interactions. The fact that PDRG is predominantly expressed in cytoplasm but not in the nucleus and its subcellular distribution does not change after UV exposure may not support the possibility that PDRG interacts with DNA. It is possible that PDRG may interact with other cytoplasmic proteins or it may oligomerize with itself. PDRG exhibits a distinct subcellular distribution that does not exhibit clear colocalization with ER-or mitochondria-specific dyes. Studies are currently in progress to determine the exact subcellular compartment in which PDRG resides.
It is interesting that UV upregulates endogenous PDRG but p53 suppresses its expression when in fact UV is known to activate wild-type p53 in both MCF-7 and HCT116 cells (Zhan et al., 1996; Adimoolam and Ford, 2002) . Both UV and p53 appear to transcriptionally affect the expression of PDRG as both alter PDRG promoter activity. The mechanisms by which p53 promotes downregulation of its target genes remain less well understood. It is now well established that p53 upregulates the expressions of its target genes by specifically binding to a consensus sequence present within the regulatory regions of p53-regulated genes. The consensus p53-binding element is composed of two 'RRRCWWGYYY' motifs that are separated by 0-to 13 nucleotides (el-Deiry et al., 1992; ResnickSilverman et al., 1998; Johnson et al., 2001) . p53 directly binds to these elements as homotetramer and also recruits other coactivators such as CBP/p300 (Gu et al., 1997) . The canonical p53-binding element that serves to promote p53-depenent upregulation exists as two 'RRRCWWGYYY' motifs arranged as head-to-head, but the repressive element carrying the same sequence has been reported to exist in head-to-tail orientation (Johnson et al., 2001) .
Three different mechanisms have been proposed by which p53 could mediate transcriptional repression of its target genes. First, it has been reported that p53, after binding to its repressive element, appears to recruit mSin3a/histone deacetylase complex and thereby mediates transcriptional repression (Murphy et al., 1999; Zilfou et al., 2001) . Second, the p53-repressive elements in the regulatory regions of target genes overlap with the response elements of other transcriptional activators. Owing to competition between p53 and other transcriptional activators for the same binding site, p53 is believed to block the accessibility of other activators to the same binding site, which results in decreased transcription. In the case of MDR1 gene promoter, the p53 repressive element has been found to overlap with Sp1-binding site. Competitive blocking of Sp1 binding to its site by p53 is thought to be the mechanism by which p53 promotes downregulation of MDR1 expression (Johnson et al., 2001) . Third, p53 is believed to transcriptionally activate the expression of certain genes whose products inhibit the expression of other genes. For example, p53 transcriptionally upregulates p21 which in turn inhibits Cdks and as a consequence there is a decreased phosphorylation of Rb (Gottifredi et al., 2001) . Dephosphorylation of Rb is believed to promote transcriptional repression of Chk1 (Gottifredi et al., 2001) . The facts that p53 inhibits PDRG promoter activity and the presence of p53 repressive element within the PDRG promoter suggest that p53 may indeed directly bind within the promoter of PDRG and suppress its expression. However, whether p53 mediates PDRG downregulation via such a mechanism remains to be elucidated.
Unlike p53, UV transcriptionally upregulates the expression of PDRG. Oct-1 is a transcription factor that belongs to POU homeodomain family and binds to target genes via its DNA-binding domain (Latchman, 1999) . Several lines of recent evidence indicate that Oct-1 appears to be involved in mediating cellular response to UV in a p53-independent manner (Zhao et al., 2000; Takahashi et al., 2001) . For example, UV has been reported to post-transcriptionally enhance the protein levels of Oct-1, which in turn transcriptionally upregu- (pCEP4) were harvested and subjected to SDS-PAGE and Western blot analysis. Western blotting was performed using an anti-HA-tag antibody (Boehringer Mannheim, Indianapolis, IN, USA) Figure 11 Expression of exogenous PDRG decreases clonogenic survival following UV irradiation. Vector-transfected or PDRGtransfected clones 14 and 16 were seeded in 100 mm plates and allowed to attach to plastic for approximately 2 days and then either not irradiated or irradiated with UV at 10 and 20 J/m 2 . After approximately 2 weeks, surviving colonies were fixed with ethanol and stained with crystal violet. Results are expressed as percent survival relative to untreated controls, which were assigned a value of 100%. The values are expressed as mean þ s.e.m. of two independent experiments p53 and DNA damage-regulated gene X Luo et al lates the expression of UV-induced genes in a p53-indpendent manner (Zhao et al., 2000; Takahashi et al., 2001) . Indeed, PDRG promoter harbors Oct-1-binding site and expression of exogenous Oct-1 strongly upregulates PDRG promoter activity. It is therefore likely that UV could mediate PDRG upregulation partly via activation of Oct-1. It is of note that UV upregulation of PDRG occurs in a p53-independent manner. Analysis of the PDRG promoter sequence reveals that Oct-1-binding element does not overlap with that of putative p53-binding site. Thus, Oct-1 and p53 both of which are activated following UV exposure could independently regulate the expression of PDRG in such a way that one promotes upregulation whereas the other would exert a negative effect. The net effect would determine the outcome whether PDRG is to be up or downregulated by UV. Our results indicate that such mechanisms could be operational with regard to PDRG regulation. For example, (i) the effect of exogenous Oct-1 on PDRG promoter activity is stronger than that of UV alone (Figure 8 , compare a and b), suggesting that concomitant activation of endogenous p53 in these cells could blunt the overall induction of PDRG promoter activity by UV and (ii) HCT116 (p53À/À) cells display higher endogenous PDRG mRNA levels than the isogenic HCT116
(p53 þ / þ ) cells (Figure 5b ), which highlights the lack of p53 repressive effects on endogenous PDRG expression in these p53-null cells. Thus, although the exact function of PDRG in mediating UV response remains to be elucidated, it is reasonable to predict that PDRG could differentially modulate UV response in p53-positive and -negative cells.
Function of PDRG remains unknown at the present time. MDR1 and 53BP2 are two other proteins that are downregulated by p53 but upregulated by UV (Lopez et al., 2000; Johnson et al., 2001) . MDR1 is involved in conferring drug resistance whereas the function of 53BP2 remains unknown (Lopez et al., 2000; Johnson et al., 2001) . Evidence suggests that 53BP2 appears to be a negative regulator of cell growth since overexpression of exogenous 53BP2 has been found to inhibit cell growth and cell cycle progression at G2/M, and promote apoptosis (Naumovski and Cleary, 1996; Yang et al., 1999; Lopez et al., 2000) . More recently, overexpression of exogenous 53BP2 has been shown to decrease clonogenic survival after UV irradiation (Lopez et al., 2000) . PDRG does not display significant sequence homology with 53BP2, and whether PDRG functions in a manner similar to 53BP2 is an issue that requires further investigations. However, based on our present results some parallels can be drawn for example, although expression of exogenous PDRG does not seem to induce apoptosis, it clearly decreases the clonogenic survival after UV irradiation. Thus, PDRG just like 53BP2 also sensitizes cells to the effects of UV. It is possible that PDRG may cooperate with other UV-regulated death-inducing molecules and thereby sensitize cells to UV-induced killing. Future studies will provide more information on how PDRG cooperates with UV to decrease clonogenic survival.
Materials and methods
Cell lines and treatment
Human breast, lung and prostate/bladder cancer cell lines MCF7, H1299 and TSUPr1, respectively, were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Gemeni Bioproducts Inc., Calabasas, CA, USA). NIH3T3 cells were maintained in DMEM (Cellgro, Mediatech, Herndon, VA, USA) supplemented with 10% calf serum (Invitrogen, Grand Island, NY, USA). HCT116
(p53 þ / þ ) and HCT116 (p53À/À) human colon cancer cells (kindly provided by Dr Bert Vogelstein, Johns Hopkins, Baltimore, MD, USA) were kept in MoCoy's 5A medium (Cellgro, Mediatech, Herndon, VA, USA) supplemented with 10% fetal bovine serum. DLD1 human colon cancer cells carrying doxycycline-inducible p53 (kindly provided by Dr Bert Vogelstein, Johns Hopkins, Baltimore, MD, USA) were maintained in DMEM supplemented with 10% fetal bovine serum and 20 ng/ml doxycycline to suppress the expression of p53. Logarithmically, growing cells were exposed to UVC essentially as described previously (Sheikh et al., 1997a) except XL-1500 UV crosslinker (Spectronics, Westbury, NY, USA) was used as a UV radiation source. Plasmids 1. To construct the PDRG expression vector, first we generated the HA-tagged PDRG ORF. Briefly, the sequence corresponding to HA-tag was incorporated into amplification primers and cDNA corresponding to the ORF of human PDRG was used as a template in amplification reactions. Following primers were used in these reactions:
The amplified product carrying HA-tag at the N-terminal end of PDRG was digested with HindIII and XhoI and subcloned into the mammalian expression vector pCEP4. The resulting vector was named pCEP-PDRG and was sequenced to confirm that it carries the correct HA-tagged PDRG sequence.
2. To create the expression vectors carrying GFP at the amino (N)-and C-terminal ends of PDRG, the ORF of PDRG was subcloned into pEGFP-C1 and the pDsRed-N1 vectors (Clontech, BD BioSciences, Palo Alto, CA, USA). The resulting vectors, named pEGFP-PDRG and pDsRed-PDRG, were sequenced to confirm correct in-frame fusion between GFP and PDRG. The vector pEGFP-PDRG carries GFP at the N-terminal end of PDRG, while pDSRed-PDRG has GFP at the C-terminal end of PDRG.
3. To construct PDRG promoter-luciferase reporter vector (pGL-full), a 1.7-kb fragment corresponding to the 5 0 -flanking region of PDRG was first amplified by PCR using a pair of primers (5 0 -AGCTCTGCCTCTGGTAGTTGAA-3 0 ; 5 0 -TAGCGCCCACCAACTCCGCT T-3 0 ) and human genomic DNA as a template. The 1.7-kb-fragment was then subcloned into the pGL-basic plasmid (Promega, Madison, WI, USA) upstream of promoterless luciferase cDNA. The promoter reporter lacking basal transcriptional region (pGL-D138) was constructed by removing the proximal 138 bp from the pGLfull using SpeI and HindIII restriction enzymes and then religating the digested vector.
4. Expression vector pCMV-p53 and the same vector without p53 insert were kindly provided by Dr Vogelstein (Johns Hopkins University, Baltimore, MD, USA). 
Northern and Western blot analyses
RNA extraction and Northern blot analyses were performed as we have previously described (Huang et al., 2001; He et al., 2002) . Briefly, cells were harvested and total RNA was extracted with TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) as per the manufacturer's instructions. Approximately 20 mg of total RNA per sample were sizefractionated onto 1.2% agarose gel, transferred to Nytran SuperCharge membranes (Schleicher & Schuell, Keene, NH, USA), and crosslinked via UV irradiation at 1200 J/m 2 .
Multitissue Northern blot carrying poly(A)
þ RNA from human brain, heart, liver, lung, spleen, stomach, testis and skeletal muscle was purchased from Panomics (Redwood City, CA, USA). Prehybridizations and hybridizations were performed in QuikHyb Solution (Stratagene, La Jolla, CA, USA) at 651C.
32 P-labeled probes were synthesized by a random primer method using Prime-It RmT Random Primer Labeling Kit (Stratagene, La Jolla, CA, USA) and purified with centrifugal filter cartridges (Amicon Centricon, Millipore, Bedford, MA, USA). Membranes were washed with appropriate buffers and the signals were visualized using autoradiographic films (Marsh Bio Products, Rochester, NY, USA). Western blot analyses were performed as we have previously described (Huang et al., 2001; He et al., 2002) . Briefly, samples were fractionated by SDS-PAGE, and then transferred to nitrocellulose membranes. Membranes were washed with PBS, blocked with 5% nonfat milk and then incubated with anti-HA or anti-GFP antibodies (both purchased from Boehringer Mannheim, Indianapolis, IN, USA) for approximately 1-2 h. Appropriate HRP-labeled secondary antibodies were used to detect signals using chemiluminescent substrate (SuperSignal, Pierce Biotechnology, Rockford, IL, USA).
Luciferase assay
1. To determine PDRG promoter activity, MCF-7 cells were transfected with approximately 0.4 mg of the following reporter vectors: pGL-full: carrying the 1.7-kb 5 0 -flanking region of human PDRG.
pGL-D138: same as pGL-full but lacks the proximal 138 nucleotides.
pGL-basic: carries the same backbone as pGL-full and pGL-D138 but contains only the promoterless luciferase without PDRG sequence.
Cells were transfected overnight with the indicated reporter vector using Mirrus transfection reagents (Fisher Scientific, Pittsburgh, PA, USA) as per the manufacturer's instructions. Cells were washed three times with medium and cultured for another 24 h prior to harvest for luciferase assay.
2. To ascertain p53 effect on PDRG promoter, various concentrations ranging from 10 ng to 1.0 mg of p53 expression vector (pCMV-p53) or the same vector without p53 insert (pCMV) were cotransfected with approximately 1.5 mg of pGL-full overnight into H1299 cells using Mirrus reagents. Cells were washed three times with medium, cultured for another 6 or 24 h and then harvested to measure luciferase activity.
3. To determine UV regulation of PDRG promoter activity, MCF7 cells seeded in six-well plates were transfected with approximately 0.5 mg of pGL-full vector along with 1.0 mg carrier DNA using Mirrus reagents for approximately 7 h, cells were washed three times with medium, cultured for another 11 h and then subjected to UV irradiation (20 J/m 2 ). Cells were harvested approximately 12 h post-UV treatment to measure luciferase activity.
4. To determine Oct-1 effect on PDRG promoter activity, approximately 1.0 mg Oct-1 expression vector or the same vector without Oct-1 insert was cotransfected with approximately 1.5 mg of pGL-full promoter overnight into MCF7 cells using Mirrus reagents. After washing off transfection solution with medium, cells were cultured for 24 h in regular media, harvested and then subjected to luciferase assay.
To measure luciferase activity, cells were resuspended in 50-70 ml of K 3 PO 4 solution (100 mm; pH 7.8) and lysed by three freeze and thaw cycles. Cell lysates were centrifuged at 13 000 r.p.m. for 10 min to separate supernatants from pellets and protein concentrations were measured by Bradford method. For each sample, 20 mg of total protein and approximately 100 ml of Luciferase Assay Reagent (Promega, Madison, WI, USA) were used to measure the luciferase activity with a luminometer (LUMAT LB 9507, Berthold Technologies, Germany).
Stable transfections
HCT116 cells were transfected with the expression vector pCEP4-PDRG or the same vector without PDRG insert. Approximately 24 h post-transfection, cells were harvested and seeded at a density of 5000 cells per 150 mm plate in the presence of 150 mg/ml hygromycin. At 14 days after drug selection, several well-isolated colonies were picked, expanded for mass culture and then screened for the expression of exogenous PDRG by Western blotting using anti-HA antibody.
Effect of UV on clonogenic survival
The effect of UV on clonogenic survival was determined as we have previously described (Sheikh et al., 1997a) . Briefly, vector-transfected or PDRG-transfected clones 14 and 16 were seeded at a density of 1 Â 10 4 cells per 100 mm plate. Cells were allowed to attach to plastic for 1 or 2 days, washed with PBS and either not exposed or exposed to UV at 10 and 20 J/m 2 . UV-treated and untreated cells were then cultured for approximately 2 weeks, colonies were fixed with ethanol, stained with 0.1% crystal violet and counted. Results were normalized with respect to untreated controls.
